Trials of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Lack Strategies to Ensure Appropriate Gastroprotection.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33982954.
- Also identified by DOI 10.14309/ajg.0000000000001134 and PMC identifier 8119932.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Gastrointestinal bleeding is a morbid complication of dual antiplatelet therapy (DAPT). We evaluated the extent to which contemporary trials of DAPT included steps to ensure appropriate use of proton pump inhibitor (PPI) gastroprotection and reported rates of PPI use. A methodological review of randomized trials comparing varying durations of DAPT after percutaneous coronary intervention. Among 21 trials, none incorporated protocol procedures or guidance for prescribing PPIs. Five reported rates of PPI use (range 25.6-69.1%). PPI gastroprotection is overlooked in major trials of DAPT. Appropriate use of PPI gastroprotection represents an important opportunity to improve patient safety.
Medical subject headings
- Clinical Trials as Topic
- Dual Anti-Platelet Therapy
- Percutaneous Coronary Intervention
- Platelet Aggregation Inhibitors
- Postoperative Care
- Practice Guidelines as Topic
- Stomach Diseases